Liquidia Corporation (LQDA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Liquidia Corporation (LQDA) Healthcare & Pipeline Overview

Liquidia Corporation is a biopharmaceutical firm specializing in advanced therapies for pulmonary arterial hypertension, notably with YUTREPIA, an inhaled dry powder treprostinil formulation. The company also distributes generic treprostinil injection, addressing unmet patient needs within the U.S. healthcare sector through its innovative product development and commercialization efforts.

What Is the Investment Thesis for LQDA?

Liquidia Corporation presents a focused investment profile within the biotechnology sector, centered on its product candidate YUTREPIA, an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH), and its existing generic treprostinil injection distribution. The company's financial metrics highlight a robust Gross Margin of 91.8%, indicating strong profitability on its product sales, alongside a Profit Margin of 7.7%. With a Market Cap of $6.04B and a P/E ratio of 44.05, the market reflects significant expectations for future growth, particularly driven by YUTREPIA's potential market penetration. Key value drivers include the successful commercialization and adoption of YUTREPIA, which aims to address unmet patient needs through a differentiated delivery mechanism. Growth catalysts are anticipated from regulatory milestones for YUTREPIA and expanded market share for its generic treprostinil injection. However, potential risks include intense competition in the PAH market, regulatory hurdles for YUTREPIA, and pricing pressures on generic products. The company's Beta of 0.42 suggests lower volatility relative to the broader market.

Based on FMP financials and quantitative analysis

LQDA Key Highlights

Market Capitalization: $6.04B, reflecting its valuation in the biotechnology sector as of the latest available data.

• Gross Margin: 91.8%, indicating strong profitability on its product sales and efficient cost management.
• Profit Margin: 7.7%, demonstrating the company's net earnings efficiency after all expenses.
• P/E Ratio: 44.05, suggesting high investor expectations for future earnings growth and market potential.
• Employee Count: 170 employees, supporting its focused biopharmaceutical development and commercialization efforts in the U.S.

Who Are LQDA's Competitors?

LQDA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LQDA's Key Strengths?

Proprietary YUTREPIA formulation offers a differentiated inhaled dry powder delivery for treprostinil.

• High Gross Margin of 91.8% indicates strong product profitability and efficient cost structure.
• Established distribution of generic treprostinil injection provides an existing revenue stream.
• Focused therapeutic area in pulmonary arterial hypertension allows for specialized market penetration.

What Are LQDA's Weaknesses?

High P/E ratio of 44.05 suggests significant future growth expectations, potentially creating valuation pressure.

• Reliance on a limited product portfolio (YUTREPIA and generic treprostinil) introduces concentration risk.
• Specific details on the CEO's extensive background and track record are not publicly provided in the source data.
• Commercialization success of YUTREPIA is critical for future growth, making the company highly dependent on its market adoption.

What Could Drive LQDA Stock Higher?

Potential regulatory approval decisions for YUTREPIA, which could significantly advance its market entry.

• Launch and initial sales performance data for YUTREPIA, providing early indicators of market adoption and commercial success.
• Continued market penetration and sales growth of the generic treprostinil injection across the United States.
• Further clinical or real-world evidence generation for YUTREPIA, potentially enhancing its differentiation and physician acceptance.

What Are the Key Risks for LQDA?

Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.

• Rich valuation — a P/E of 44.05 runs well above the Healthcare sector’s ~21.60x, leaving little room for a miss.
• Insider selling — insiders were net sellers of roughly $71.3M recently.
• Regulatory hurdles or delays for YUTREPIA's full commercialization and market access in the United States.
• Challenges in securing broad market adoption for YUTREPIA against established and competing pulmonary arterial hypertension therapies.
• Intense competition within the biotechnology sector, particularly from companies developing treatments for pulmonary arterial hypertension.
• Pricing pressures and market erosion affecting the profitability and market share of the generic treprostinil injection.
• Dependence on a limited product portfolio, making the company susceptible to the success or failure of its key products.

What Are the Growth Opportunities for LQDA?

• Expanded Commercialization of YUTREPIA: Liquidia's primary growth opportunity lies in the successful commercialization and market penetration of YUTREPIA, its inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH) in the United States. This involves increasing physician adoption and patient prescriptions by highlighting the potential benefits of its unique delivery method. The PAH market represents a significant therapeutic area.
• Growth in Generic Treprostinil Injection Market Share: Another key growth driver is the expansion of Liquidia's market share in the distribution of generic treprostinil injection across the United States. By leveraging competitive strategies and efficient supply chain management, the company aims to capture a larger segment of the established generic market.
• Differentiation through YUTREPIA's Delivery Mechanism: Liquidia can drive growth by emphasizing the distinct advantages of YUTREPIA's inhaled dry powder formulation. This differentiation in drug delivery could lead to improved patient adherence and convenience compared to other treprostinil formulations, potentially expanding the addressable patient population or securing preference among prescribing physicians.
• Optimizing the Treprostinil Portfolio Synergy: The company's unique position of offering both a novel inhaled formulation (YUTREPIA) and a generic injectable treprostinil allows for potential synergies in market access, sales force effectiveness, and overall brand recognition within the treprostinil therapeutic space. This integrated approach could enhance Liquidia's competitive standing and drive combined revenue growth.
• Addressing Unmet Needs in PAH Treatment: Liquidia's focus on "unmet patient needs" with YUTREPIA positions it to capture demand from patients who may not be adequately managed by existing therapies or who seek less invasive delivery methods. Continuous engagement with the patient and physician community to identify and address these specific needs can fuel sustained growth for its PAH-focused products.

What Are LQDA's Competitive Advantages?

• Proprietary inhaled dry powder formulation of treprostinil (YUTREPIA), offering a differentiated delivery method for PAH treatment.
• Expertise in developing and commercializing specialized biopharmaceutical products for specific therapeutic areas.
• Established distribution network and market presence for generic treprostinil injection in the United States.
• Focus on addressing unmet patient needs, potentially leading to strong physician and patient adoption for innovative solutions.

What Does LQDA Do?

Liquidia Corporation, founded in 2004 and headquartered in Morrisville, North Carolina, is a biopharmaceutical company dedicated to the development, manufacture, and commercialization of products aimed at addressing unmet patient needs across the United States. The company operates within the dynamic healthcare sector, specifically focusing its efforts within the biotechnology industry. Liquidia's strategic approach involves both the innovation of novel drug delivery systems and the distribution of established generic medications. A cornerstone of its product portfolio is YUTREPIA, an inhaled dry powder formulation of treprostinil. This product candidate is specifically designed for the treatment of pulmonary arterial hypertension (PAH), a chronic and progressive disease that affects the arteries in the lungs and heart. YUTREPIA represents Liquidia's commitment to advancing therapeutic options by offering a potentially differentiated delivery method for a critical medication. Beyond its pipeline innovation, Liquidia Corporation also plays a role in the broader pharmaceutical market by distributing generic treprostinil injection in the United States. This dual strategy allows the company to engage with both the innovative and established segments of the treprostinil market. With 170 employees, Liquidia maintains a focused operational structure to support its research, development, manufacturing, and commercialization activities, aiming to deliver value through its specialized product offerings and market presence in the U.S. healthcare landscape.

What Products and Services Does LQDA Offer?

• Develops and manufactures biopharmaceutical products for unmet patient needs in the United States.
• Commercializes its product candidates and distributed products within the U.S. healthcare market.
• Offers YUTREPIA, an inhaled dry powder formulation of treprostinil, as a key product candidate.
• YUTREPIA is specifically developed for the treatment of pulmonary arterial hypertension (PAH).
• Distributes generic treprostinil injection across the United States.
• Operates within the biotechnology industry, focusing on specialized therapeutic areas.
• Aims to provide differentiated therapeutic options through innovative drug delivery methods.

How Does LQDA Make Money?

• Generates revenue from the sales and distribution of generic treprostinil injection in the United States.
• Anticipates future revenue streams from the commercialization and sales of its product candidate, YUTREPIA, for pulmonary arterial hypertension.
• Invests in research and development to create novel formulations and product candidates addressing specific unmet patient needs.
• Engages in manufacturing processes for its proprietary products and manages supply chains for distributed generics.

What Industry Does LQDA Operate In?

Liquidia Corporation operates within the highly specialized and competitive biotechnology industry, a sub-sector of healthcare. Its primary focus on pulmonary arterial hypertension (PAH) places it within a niche therapeutic area characterized by significant unmet patient needs and ongoing innovation in drug delivery. The broader biotechnology market is driven by advancements in drug discovery, novel formulations, and targeted therapies. Liquidia's strategy of developing an inhaled dry powder formulation for treprostinil, a known PAH treatment, positions it to potentially capture market share by offering a differentiated patient experience compared to existing injectable or nebulized options. The competitive landscape includes established pharmaceutical companies with existing PAH treatments and other biotech firms developing new therapies or generic versions of existing drugs. Liquidia's dual approach of innovative product development and generic distribution allows it to navigate both the high-growth, high-risk innovative segment and the more stable, volume-driven generic market within the U.S. healthcare system.

Who Are LQDA's Key Customers?

• Patients diagnosed with pulmonary arterial hypertension (PAH) who require treprostinil therapy.
• Healthcare providers, including pulmonologists and cardiologists, who prescribe treprostinil.
• Hospitals, clinics, and pharmacies that stock and dispense treprostinil products.
• Healthcare systems and payers that manage access to pharmaceutical treatments.

Company Profile

Liquidia Corporation operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Morrisville, US. The company is led by CEO Roger A. Jeffs. LQDA has traded publicly since 2018.

Return on equity for Liquidia Corporation stands at 149.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 26.6%, showing how much profit it generates from its asset base. LQDA trades at a trailing price-to-earnings ratio of 44.05, above the Healthcare sector average of ~21.60x. Its free cash flow yield is 1.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.8%, the inverse of the P/E and a quick read on earnings relative to price.

LQDA Valuation & Market Position

With a $6.04B market cap, Liquidia Corporation sits in the mid-cap segment of the market. Analyst price targets span from $36.00 to $130.00, with a consensus of $98.11. At the current price of $67.97, that implies approximately 44% upside potential. Relative to its peer group, LQDA's quantitative score of 96/100 is above the peer average of 76/100.

Quarterly Financial Performance: Liquidia Corporation

Revenue for Liquidia Corporation came in at $171.7M during Q2 FY2026, a 29.2% improvement versus the preceding quarter. The company recorded net income of $74.7M, with diluted EPS of $0.74. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, LQDA averaged $0.34 in diluted EPS.

Liquidia Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 12.26 places it in the safe zone, indicating low near-term bankruptcy risk.

Liquidia Corporation has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 23.4% above estimates on average.

Over the past six months, Liquidia Corporation insiders filed 100 SEC Form 4 transactions — 68 sales and 32 purchases. On net that is roughly 869K shares disposed (about $71.3M), a signal worth weighing alongside the fundamentals.

LQDA Financials

LQDA Latest News

LQDA Analyst Consensus

LQDA MoonshotScore

Latest Liquidia Corporation Analysis

LQDA Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources